Theoretically, TK inhibition was expected to be an effective cure for CML, and imatinib, which competitively inhibits phosphorylation of BCR-ABL1, was developed in 2001 and is used as a frontline TK inhibitor (TKI) [2–5]. Here, TKT is linked to chronic myelogenous leukemia, BCR-ABL1 positive.